This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.
Adult patients (≥ 18 years old).
Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART
Written informed consent voluntarily provided
Patients not fulfilling the eligibility criteria
Fondazione Italiana Linfomi - ETS
Lead sponsor
Kite, A Gilead Company
Collaborator